BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20697713)

  • 1. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
    Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)].
    Sova P; Chladek J; Zak F; Mistr A; Kroutil A; Semerad M; Slovak Z
    Int J Pharm; 2005 Jan; 288(1):123-9. PubMed ID: 15607264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.
    Cermanova J; Chladek J; Soval P; Kroutil A; Semerad M; Berankova Z; Siroky P; Surova I
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):679-85. PubMed ID: 15632953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
    Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
    Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
    Zák F; Turánek J; Kroutil A; Sova P; Mistr A; Poulová A; Mikolin P; Zák Z; Kasná A; Záluská D; Neca J; Sindlerová L; Kozubík A
    J Med Chem; 2004 Jan; 47(3):761-3. PubMed ID: 14736257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in rats.
    Cho YB; Kim DK; Kim KH; Miyamoto G
    Arzneimittelforschung; 1996 Jun; 46(6):629-34. PubMed ID: 8767356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.
    Sova P; Mistr A; Kroutil A; Zak F; Pouckova P; Zadinova M
    Anticancer Drugs; 2005 Jul; 16(6):653-7. PubMed ID: 15930894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H; Park C; Yao M
    Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satraplatin: an orally available platinum analog for the treatment of cancer.
    Choy H
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
    Theiner S; Varbanov HP; Galanski MS; Egger AE; Berger W; Heffeter P; Keppler BK
    J Biol Inorg Chem; 2015 Jan; 20(1):89-99. PubMed ID: 25413442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats.
    Liu QF; Li X; Su Q; Luo GA; Wang YM; Liu WP
    Arch Pharm Res; 2009 Nov; 32(11):1621-8. PubMed ID: 20091277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
    Bakhteeva VT; Fok EM; Lavrova EA
    Vopr Med Khim; 1996; 42(4):301-6. PubMed ID: 9254514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice.
    Kido Y; Khokhar AR; Siddik ZH
    Drug Metab Dispos; 1992; 20(5):673-8. PubMed ID: 1358571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.